{"article_title": "Why clinical trial recruitment is so hard, and one solution: Patient education", "article_keywords": ["patient", "cancer", "trial", "trials", "hard", "solution", "recruitment", "patients", "clinical", "treatment", "stigma", "education", "experimental"], "article_url": "http://medcitynews.com/2015/03/challenges-clinical-trial-recruitment/", "article_text": "Clinical trials are the lifeblood of the life sciences industry \u2013 yet less than 5 percent of adult cancer patients will pursue experimental therapies. The biggest reason for this? Fear:\n\n\u201cAlthough the backbone of today\u2019s successful cancer treatments, clinical trials are poorly understood by the public, often viewed as treating people like guinea pigs instead of as giving them the best chance for survival,\u201d a piece today in the New York Times says.\n\nThe article is patient-centric and patient-geared: It serves as a much-needed call-to-action for the many would-be clinical trial participants. Such patient education efforts are really critical in helping bump up enrollment figures \u2013 which ultimately get that biologic, small molecule or miracle stent approved and on the market.\n\nAdvertisement\n\nAn article from OncLive outlines the different challenges in clinical trial recruitment:\n\nFear : Patients are afraid of being placed in the placebo docket, and thereby missing treatment entirely.\n\n: Patients are afraid of being placed in the placebo docket, and thereby missing treatment entirely. Stigma : Clinical trials are shrouded in stigma. Patients look at clinical trials as last resort options \u2013 and often believe that a drug\u2019s more legit if it\u2019s got the FDA stamp of approval.\n\n: Clinical trials are shrouded in stigma. Patients look at clinical trials as last resort options \u2013 and often believe that a drug\u2019s more legit if it\u2019s got the FDA stamp of approval. Confusion : Clinical trials can be complicated and confusing, and refusing the paperwork, the routines and the possible travel are far easier an option than going ahead with an experimental therapy.\n\n: Clinical trials can be complicated and confusing, and refusing the paperwork, the routines and the possible travel are far easier an option than going ahead with an experimental therapy. Insurance : Patients may get the run-around from insurance companies on whether these trials will be covered. Despite protections in the Affordable Care Act, insured patients might be concerned of unexpected costs \u2013 and many don\u2019t know what rights they have within their plans.\n\n: Patients may get the run-around from insurance companies on whether these trials will be covered. Despite protections in the Affordable Care Act, insured patients might be concerned of unexpected costs \u2013 and many don\u2019t know what rights they have within their plans. Burden: Patients are worried about burdening their families, and will often choose the easiest course of treatment, even if it isn\u2019t the best one.\n\nThere\u2019s hope, though, and a precedent of success: Parents of children with cancer are far more likely to pursue experimental therapies \u2013 and it\u2019s paid dividends.\n\n\u201cThe outcome in children is so stunning because 80 to 90 percent of young patients participate in clinical trials,\u201d Siddhartha Mukherjee, author of the Pulitzer Prize-winning book, \u201cThe Emperor of All Maladies: A Biography of Cancer,\u201d told the New York Times. \u201cEvery trial taught doctors something that led to further trials and better results.\u201d\n\nA 2008 paper in Lancet Oncology attributed \u201cthis high level of engagement\u201d to the \u201cso-called therapeutic alliance that begins between doctors and families when a child is diagnosed with cancer.\u201d In the patient education game, pediatric specialists are interfacing more effectively with parents than adult docs are with their own patients. So how do you expand this success rate to the much larger adult cancer patient set? The OncLive piece suggests:\n\nEveryone agreed that communication and education were essential in overcoming the fear-based patient and family barriers to clinical trials. Some specific approaches, mostly focused on healthcare professionals\u2019 involvement, included the following: Provide all the treatment options, including eligible clinical trials, to the patients and their families. Involve them in the decision-making, and engage everyone in the conversation. Recognize that all healthcare professionals have a role in recruitment, including oncologists, nurses, surgeons, social workers, and primary care providers. Educate patients so that they know that clinical trials offer a type of treatment rather than a placebo.\n\nA strong patient education agenda should be budgeted into every life sciences company\u2019s product development plan. Interfacing with both doctors and patient communities is key.\n\nAnd articles like today\u2019s in the NYT help. They allow the greater public a more transparent view of clinical trials, and how they work. Having this enter the greater dialogue should slowly encourage patients to become willing trial participants.\n\n[Photo courtesy of Flickr user DES Daughter]", "article_metadata": {"description": "Clinical trials are the lifeblood of the life sciences industry \u2013 yet less than\u00a05 percent of adult cancer patients will pursue experimental therapies.\u00a0The biggest reason for this? Fear: \u201cAlthough the backbone of today\u2019s successful cancer treatments, clinical trials are poorly understood by the public, often viewed as treating people like guinea pigs instead of as giving them the best chance for survival,\u201d a piece today in the\u00a0New York Times\u00a0says. The article is patient-centric and patient-geared: It serves as a much-needed call-to-action for the many would-be clinical trial participants. Such patient education efforts are really critical in helping bump up enrollment figures \u2013 which ultimately get that biologic, small molecule or miracle stent approved and on the market. An\u00a0article from\u00a0OncLive outlines the different challenges in clinical trial recruitment: Fear: Patients are afraid of being placed in the placebo docket, and thereby missing treatment entirely. Stigma:\u00a0Clinical trials are shrouded in stigma. Patients look at clinical trials as last resort options \u2013 and often believe that a drug\u2019s more legit if it\u2019s got the FDA stamp of approval. Confusion: Clinical trials can be complicated and confusing, and refusing the paperwork, the routines and the possible travel are far easier an option than going ahead with an experimental therapy. Insurance: Patients may get the run-around from insurance companies on whether these trials will be covered. Despite protections in the Affordable Care Act, insured patients might be concerned of unexpected costs \u2013 and many don\u2019t know what rights they have within their plans. Burden: Patients are worried about burdening their families, and will often choose the easiest course of treatment, even if it isn\u2019t the best one. There\u2019s hope, though, and a precedent of success: Parents of children with cancer are far more likely to pursue experimental therapies \u2013 and it\u2019s paid dividends. \u201cThe outcome in children is so stunning because 80 to 90 percent of young patients participate in clinical trials,\u201d Siddhartha\u00a0Mukherjee, author of the Pulitzer Prize-winning\u00a0book, \u201cThe Emperor of All Maladies: A Biography of Cancer,\u201d told the New York Times. \u201cEvery trial taught doctors something that led to further trials and better results.\u201d A 2008 paper in\u00a0Lancet Oncology\u00a0attributed \u201cthis high level of engagement\u201d to the \u201cso-called therapeutic alliance that begins between doctors and families when a child is diagnosed with cancer.\u201d\u00a0In the patient education game, pediatric specialists are interfacing more effectively with parents than adult docs are with their own patients.\u00a0So how do you expand this success rate to the much larger adult cancer patient set? The\u00a0OncLive\u00a0piece suggests: Everyone agreed that communication and education were essential in overcoming the fear-based patient and family barriers to clinical trials. Some specific approaches, mostly focused on healthcare professionals\u2019 involvement, included the following: Provide all the treatment options, including eligible clinical trials, to the patients and their families. Involve them in the decision-making, and engage everyone in the conversation. Recognize that all healthcare professionals have a role in recruitment, including oncologists, nurses, surgeons, social workers, and primary care providers. Educate patients so that they know that clinical trials offer a type of treatment rather than a placebo. A strong patient education agenda\u00a0should be budgeted into every life sciences company\u2019s product development plan. Interfacing with both doctors and patient communities is key. And articles like today\u2019s in the NYT\u00a0help. They allow the greater public\u00a0a more transparent view of clinical trials, and how they work. Having this enter the greater dialogue should slowly encourage patients to become\u00a0willing trial participants. [Photo courtesy of Flickr user DES Daughter]", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Clinical trials are the lifeblood of the life sciences industry \u2013 yet less than\u00a05 percent of adult cancer patients will pursue experimental therapies.\u00a0The biggest reason for this? Fear: \u201cAlthough the backbone of today\u2019s successful cancer treatments, clinical trials are poorly understood by the public, often viewed as treating people like guinea pigs instead of as giving them the best chance for survival,\u201d a piece today in the\u00a0New York Times\u00a0says. The article is patient-centric and patient-geared: It serves as a much-needed call-to-action for the many would-be clinical trial participants. Such patient education efforts are really critical in helping bump up enrollment figures \u2013 which ultimately get that biologic, small molecule or miracle stent approved and on the market. An\u00a0article from\u00a0OncLive outlines the different challenges in clinical trial recruitment: Fear: Patients are afraid of being placed in the placebo docket, and thereby missing treatment entirely. Stigma:\u00a0Clinical trials are shrouded in stigma. Patients look at clinical trials as last resort options \u2013 and often believe that a drug\u2019s more legit if it\u2019s got the FDA stamp of approval. Confusion: Clinical trials can be complicated and confusing, and refusing the paperwork, the routines and the possible travel are far easier an option than going ahead with an experimental therapy. Insurance: Patients may get the run-around from insurance companies on whether these trials will be covered. Despite protections in the Affordable Care Act, insured patients might be concerned of unexpected costs \u2013 and many don\u2019t know what rights they have within their plans. Burden: Patients are worried about burdening their families, and will often choose the easiest course of treatment, even if it isn\u2019t the best one. There\u2019s hope, though, and a precedent of success: Parents of children with cancer are far more likely to pursue experimental therapies \u2013 and it\u2019s paid dividends. \u201cThe outcome in children is so stunning because 80 to 90 percent of young patients participate in clinical trials,\u201d Siddhartha\u00a0Mukherjee, author of the Pulitzer Prize-winning\u00a0book, \u201cThe Emperor of All Maladies: A Biography of Cancer,\u201d told the New York Times. \u201cEvery trial taught doctors something that led to further trials and better results.\u201d A 2008 paper in\u00a0Lancet Oncology\u00a0attributed \u201cthis high level of engagement\u201d to the \u201cso-called therapeutic alliance that begins between doctors and families when a child is diagnosed with cancer.\u201d\u00a0In the patient education game, pediatric specialists are interfacing more effectively with parents than adult docs are with their own patients.\u00a0So how do you expand this success rate to the much larger adult cancer patient set? The\u00a0OncLive\u00a0piece suggests: Everyone agreed that communication and education were essential in overcoming the fear-based patient and family barriers to clinical trials. Some specific approaches, mostly focused on healthcare professionals\u2019 involvement, included the following: Provide all the treatment options, including eligible clinical trials, to the patients and their families. Involve them in the decision-making, and engage everyone in the conversation. Recognize that all healthcare professionals have a role in recruitment, including oncologists, nurses, surgeons, social workers, and primary care providers. Educate patients so that they know that clinical trials offer a type of treatment rather than a placebo. A strong patient education agenda\u00a0should be budgeted into every life sciences company\u2019s product development plan. Interfacing with both doctors and patient communities is key. And articles like today\u2019s in the NYT\u00a0help. They allow the greater public\u00a0a more transparent view of clinical trials, and how they work. Having this enter the greater dialogue should slowly encourage patients to become\u00a0willing trial participants. [Photo courtesy of Flickr user DES Daughter]", "title": "Why clinical trial recruitment is so hard, and one solution: Patient education", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/Screen-Shot-2015-03-23-at-11.05.03-AM.png", "updated_time": "2015-03-23T14:08:19-04:00", "url": "http://medcitynews.com/2015/03/challenges-clinical-trial-recruitment/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/Screen-Shot-2015-03-23-at-11.05.03-AM.png", "creator": "@meghanakeshavan", "description": "Clinical trials are the lifeblood of the life sciences industry \u2013 yet less than\u00a05 percent of adult cancer patients will pursue experimental therapies.\u00a0The biggest reason for this? Fear: \u201cAlthough the backbone of today\u2019s successful cancer treatments, clinical trials are poorly understood by the public, often viewed as treating people like guinea pigs instead of as giving them the best chance for survival,\u201d a piece today in the\u00a0New York Times\u00a0says. The article is patient-centric and patient-geared: It serves as a much-needed call-to-action for the many would-be clinical trial participants. Such patient education efforts are really critical in helping bump up enrollment figures \u2013 which ultimately get that biologic, small molecule or miracle stent approved and on the market. An\u00a0article from\u00a0OncLive outlines the different challenges in clinical trial recruitment: Fear: Patients are afraid of being placed in the placebo docket, and thereby missing treatment entirely. Stigma:\u00a0Clinical trials are shrouded in stigma. Patients look at clinical trials as last resort options \u2013 and often believe that a drug\u2019s more legit if it\u2019s got the FDA stamp of approval. Confusion: Clinical trials can be complicated and confusing, and refusing the paperwork, the routines and the possible travel are far easier an option than going ahead with an experimental therapy. Insurance: Patients may get the run-around from insurance companies on whether these trials will be covered. Despite protections in the Affordable Care Act, insured patients might be concerned of unexpected costs \u2013 and many don\u2019t know what rights they have within their plans. Burden: Patients are worried about burdening their families, and will often choose the easiest course of treatment, even if it isn\u2019t the best one. There\u2019s hope, though, and a precedent of success: Parents of children with cancer are far more likely to pursue experimental therapies \u2013 and it\u2019s paid dividends. \u201cThe outcome in children is so stunning because 80 to 90 percent of young patients participate in clinical trials,\u201d Siddhartha\u00a0Mukherjee, author of the Pulitzer Prize-winning\u00a0book, \u201cThe Emperor of All Maladies: A Biography of Cancer,\u201d told the New York Times. \u201cEvery trial taught doctors something that led to further trials and better results.\u201d A 2008 paper in\u00a0Lancet Oncology\u00a0attributed \u201cthis high level of engagement\u201d to the \u201cso-called therapeutic alliance that begins between doctors and families when a child is diagnosed with cancer.\u201d\u00a0In the patient education game, pediatric specialists are interfacing more effectively with parents than adult docs are with their own patients.\u00a0So how do you expand this success rate to the much larger adult cancer patient set? The\u00a0OncLive\u00a0piece suggests: Everyone agreed that communication and education were essential in overcoming the fear-based patient and family barriers to clinical trials. Some specific approaches, mostly focused on healthcare professionals\u2019 involvement, included the following: Provide all the treatment options, including eligible clinical trials, to the patients and their families. Involve them in the decision-making, and engage everyone in the conversation. Recognize that all healthcare professionals have a role in recruitment, including oncologists, nurses, surgeons, social workers, and primary care providers. Educate patients so that they know that clinical trials offer a type of treatment rather than a placebo. A strong patient education agenda\u00a0should be budgeted into every life sciences company\u2019s product development plan. Interfacing with both doctors and patient communities is key. And articles like today\u2019s in the NYT\u00a0help. They allow the greater public\u00a0a more transparent view of clinical trials, and how they work. Having this enter the greater dialogue should slowly encourage patients to become\u00a0willing trial participants. [Photo courtesy of Flickr user DES Daughter]", "card": "summary", "title": "Why clinical trial recruitment is so hard, and one solution: Patient education - MedCity News"}, "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,Clinical Trials, hospitals, medical devices, pharmaceuticals, Startups, , MedCity News", "article": {"section": "Daily", "tag": "Startups", "published_time": "2015-03-23T14:06:10-04:00", "modified_time": "2015-03-23T14:08:19-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "article_summary": "The article is patient-centric and patient-geared: It serves as a much-needed call-to-action for the many would-be clinical trial participants.\nStigma : Clinical trials are shrouded in stigma.\nA strong patient education agenda should be budgeted into every life sciences company\u2019s product development plan.\nThey allow the greater public a more transparent view of clinical trials, and how they work.\nSuch patient education efforts are really critical in helping bump up enrollment figures \u2013 which ultimately get that biologic, small molecule or miracle stent approved and on the market."}